A comparison of expression levels across breast cancer subtypes revealed an upregulation of the readers IGF2BP1, IGF2BP2, and IGF2BP3 in basal cases, whereas other m6A readers manifested a more homogeneous expression across subtypes (Fig. 1A–D and Supplementary Fig. S2C–H). This evidence concerns the gene IGF2BP3 and breast carcinoma.